Lv11
50 积分 2024-08-17 加入
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
3小时前
待确认
Three-year follow-up analysis of first-line axicabtagene ciloleucel in high-risk large B-cell lymphoma (ZUMA-12)
1个月前
已完结
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
1个月前
已完结
CD19-Directed CAR-T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
1个月前
已完结
Chimeric Antigen Receptor T-cell Therapy for Richter Transformation: A CIBMTR analysis
1个月前
已关闭
Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
1个月前
已完结
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
1个月前
已完结
Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study
1个月前
已完结
CD19 CAR-T with axicabtagene ciloleucel in r/r large B-cell lymphoma with/without prior autologous stem cell transplant
1个月前
已完结
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry
1个月前
已完结
皖公网安备34019202002308
